April 26, 2024
Cigna’s Evernorth Pushes for Increased Humira Biosimilar Adoption
Cigna, Evernorth, Humira, biosimilars, healthcare, pharmacy services, cost savings, patient access, AbbVie
Novo Nordisk Faces Scrutiny Over High Prices of Ozempic and Wegovy
Novo Nordisk, Ozempic, Wegovy, drug prices, Senator Bernie Sanders, diabetes, obesity
Sanofi Eyes COPD Treatment as Major Growth Driver for Dupixent, Says CEO
Sanofi, Dupixent, COPD, growth pillar, immunology, CEO, treatment, expansion, clinical trials, asthma, atopic dermatitis.
Gilead’s Strategic Focus: CymaBay Liver Drug, Trodelvy Data, and Long-Acting PrEP in 2023
Gilead, CymaBay, liver drug, Trodelvy, readouts, long-acting PrEP, 2023, strategic focus.
UCB’s Strategic Shift: Bristol Myers ADC Partner’s CEO Takes the Helm
UCB, management changes, CEO, Bristol Myers, ADC partner, strategic shift, pharmaceutical industry.
FDA Approves Pfizer’s Hemophilia B Gene Therapy with a $3.5 Million Price Tag
Pfizer, FDA, hemophilia B, gene therapy, approval, pricing, healthcare, biotechnology, rare diseases, genetic disorders, treatment cost.
GSK Files Lawsuit Against Pfizer and BioNTech for Alleged COVID-19 Vaccine Patent Violation
GSK, Pfizer, BioNTech, COVID-19, patent infringement, vaccine, lawsuit, intellectual property
BMS Realigns Workforce Post-Mergers and Acquisitions: A Strategic Move Affecting 2,200 Employees
BMS, layoffs, mergers and acquisitions, workforce realignment, strategic move, 2, 200 employees
Endo’s Par Pharmaceutical Recalls Blood Pressure Medication Due to Potential Contamination
Endo, Par Pharmaceutical, recall, blood pressure medication, contamination, quinapril HCl/ hydrochlorothiazide tablets, USP 20 mg/12.5 mg, lot number 0KG190092, expiration date 03/2022
Regeneron Pharmaceuticals Expands Gene Editing Capabilities with Mammoth Biosciences Partnership
Regeneron, Mammoth Biosciences, gene editing, CRISPR, partnership, biotechnology, healthcare, pharmaceuticals, genetic research, therapeutic development.